GlassScriptPhysician profile
Gerald J Hausler
NPI 1902988561
$15,701.87
in general payments reported to CMS, 2019-2025
64 companies · $3,233 in 2025
The $3,233 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,838 · 2020: $1,639 · 2021: $2,827 · 2022: $2,296 · 2023: $2,088 · 2024: $1,780 · 2025: $3,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,061 · Consulting Fee: $2,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,061.35 |
| Consulting Fee | $2,040.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renalytix Ai, INC. | $2,237.31 | 2022-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Abbvie INC. | $2,085.87 | 2019-2025 | |
| Novo Nordisk INC | $1,295.61 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $1,177.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $975.03 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $733.71 | 2019-2025 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $598.18 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $526.29 | 2019-2024 | Evenity, Prolia, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $523.23 | 2021-2025 | |
| Lilly USA, LLC | $517.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $407.76 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $379.14 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $328.92 | 2019-2024 | Verquvo, Steglatro, Belsomra |
| Astellas Pharma US INC | $285.64 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $264.67 | 2019-2025 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Hausler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.